Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update

Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection

(2014) Francois Ghiringhelli et al.   ANNALS OF SURGICAL ONCOLOGY

Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors

(2014) Diego O. Croci et al.   CELL

Characterization and cancer cell targeted imaging properties of human antivascular endothelial growth factor monoclonal antibody conjugated CdTe/ZnS quantum dots

(2014) Lili Pang et al.   LUMINESCENCE

Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy

(2013) Oguz Kara et al.   Asian Pacific Journal of Cancer Prevention

MicroRNA-126 and epidermal growth factor-like domain 7–an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

(2013) T F Hansen et al.   BRITISH JOURNAL OF CANCER

Cancer heterogeneity: implications for targeted therapeutics

(2013) R Fisher et al.   BRITISH JOURNAL OF CANCER

Tumor cell response to bevacizumab single agent therapy in vitro

(2013) Melanie Hein et al.   Cancer Cell International

Neuropilin 1: function and therapeutic potential in cancer

(2013) Belal Chaudhary et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents

(2013) Gabriel Limaverde-Sousa et al.   CANCER TREATMENT REVIEWS

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy

(2013) M. Selvakumaran et al.   CLINICAL CANCER RESEARCH

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy

(2013) N. R. Smith et al.   CLINICAL CANCER RESEARCH

Tumor associated macrophages and neutrophils in cancer

(2013) Maria Rosaria Galdiero et al.   IMMUNOBIOLOGY

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab

(2013) Irene Guijarro-Muñoz et al.   MEDICAL ONCOLOGY

Early Vessel Destabilization Mediated by Angiopoietin-2 and Subsequent Vessel Maturation via Angiopoietin-1 Induce Functional Neovasculature after Ischemia

(2013) Di Qin et al.   PLoS One

Detection of VEGF-Axxxb Isoforms in Human Tissues

(2013) David O. Bates et al.   PLoS One

Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases

(2013) M. Gil et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Guidelines for the use and interpretation of assays for monitoring autophagy

(2012) Daniel J. Klionsky et al.   Autophagy

Pericyte-Coverage of Human Tumor Vasculature and Nanoparticle Permeability

(2012) Liuzhe Zhang et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases

(2012) S De Bruyne et al.   BRITISH JOURNAL OF CANCER

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

(2012) D. O. Bates et al.   CLINICAL CANCER RESEARCH

Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy

(2012) A. McIntyre et al.   CLINICAL CANCER RESEARCH

Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities

(2012) Renata Ferrarotto et al.   Clinical Colorectal Cancer

Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms

(2012) Fausto Gueths Gomes et al.   LIFE SCIENCES

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Tumor Lymphangiogenesis as a Potential Therapeutic Target

(2012) Tam Duong et al.   Journal of Oncology

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression

(2011) M. Franco et al.   BLOOD

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

(2011) Steven G Patten et al.   BMC CANCER

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas

(2011) Qingguo Li et al.   BMC CANCER

Spectral imaging-based methods for quantifying autophagy and apoptosis

(2011) Nathan G. Dolloff et al.   CANCER BIOLOGY & THERAPY

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

(2011) Kristoffer Staal Rohrberg et al.   CANCER BIOLOGY & THERAPY

Molecular Predictors of Response to Antiangiogenesis Therapies

(2011) Armin Gerger et al.   CANCER JOURNAL

Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy

(2011) B. Sitohy et al.   CANCER RESEARCH

p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers

(2011) P. Sundaram et al.   CANCER RESEARCH

Gene Expression of Vascular Endothelial Growth Factor A, Thymidylate Synthase, and Tissue Inhibitor of Metalloproteinase 3 in Prediction of Response to Bevacizumab Treatment in Colorectal Cancer Patients

(2011) Toshiaki Watanabe et al.   DISEASES OF THE COLON & RECTUM

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables

(2011) Yalai Bai et al.   LABORATORY INVESTIGATION

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy

(2011) J. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature

(2011) M. Pohl et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored

(2011) Elham Fakhrejahani et al.   Journal of Oncology

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

(2010) V Goede et al.   BRITISH JOURNAL OF CANCER

Vascular endothelial growth factor receptor-1 in human cancer

(2010) Jonathan D. Schwartz et al.   CANCER

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

(2010) N. R. Smith et al.   CLINICAL CANCER RESEARCH

Is VEGF a predictive biomarker to anti-angiogenic therapy?

(2010) Zaher K. Otrock et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

(2010) Iris Helfrich et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Proteomics of colorectal cancer: Overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers

(2010) Connie R. Jimenez et al.   Journal of Proteomics

Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas

(2010) Daniela Furlan et al.   MODERN PATHOLOGY

miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1

(2010) J. D. Roybal et al.   MOLECULAR CANCER RESEARCH

Endothelial-Mural Cell Signaling in Vascular Development and Angiogenesis

(2009) Konstantin Gaengel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

(2009) Yong Sang Hong et al.   BMC CANCER

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

VEGF121b, a new member of the VEGF xxx b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo

(2009) E S Rennel et al.   BRITISH JOURNAL OF CANCER

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

(2009) L. Xu et al.   CANCER RESEARCH

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

(2009) Marja Lohela et al.   CURRENT OPINION IN CELL BIOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability

(2009) Virginia Espina et al.   Proteomics Clinical Applications

VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

(2008) A H R Varey et al.   BRITISH JOURNAL OF CANCER

Molecular Basis for the Induction of an Angiogenesis Inhibitor, Thrombospondin-1, by 5-Fluorouracil

(2008) H.-Y. Zhao et al.   CANCER RESEARCH

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies

(2008) Farbod Shojaei et al.   DRUG RESISTANCE UPDATES

The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes

(2007) Vadim Tchaikovski et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY